however, since then, four states (California, New Hampshire, Pennsylvania, and South Carolina) have eliminated coverage of GLP-1s for obesity treatment, likely reflecting recent state budget challenges and the significant costs associated with coverage
Semaglutide is a GLP-1 receptor agonist that mimics a natural hormone your intestines produce after eating
For those wondering about the process, semaglutide is typically administered as a weekly injection under the skin
23,24 CLINICAL STUDIES Many clinical trials have been completed with oral semaglutide in support of the manufacturer's submission to the FDA seeking approval for the treatment of T2DM
That is why it works as a once-weekly injection, unlike older GLP-1 agonists that required daily dosing